Literature DB >> 29198002

Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.

Erik V Soloff1, Atif Zaheer2, Jeffrey Meier3, Marc Zins4, Eric P Tamm5.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a relatively common malignancy that carries an overall poor prognosis, with five-year survival below 10%. Despite ongoing research, surgical resection remains the only potentially curative treatment. Therefore, accurate identification of those patients who would benefit from surgical resection is of paramount importance. High-quality imaging and image interpretation is central to this process. Radiology helps in the determination of whether patients are resectable, borderline resectable, or unresectable and guides treatment planning.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma (PDAC); Preoperative staging; Resectability; Vasculature

Mesh:

Year:  2018        PMID: 29198002     DOI: 10.1007/s00261-017-1410-2

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  4 in total

Review 1.  Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.

Authors:  D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser
Journal:  J Gastrointest Oncol       Date:  2020-04

2.  A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.

Authors:  Jiachen Ge; Lei Li; Zhaolai Ma; Bin Jiang; Chunhui Yuan; Hangyan Wang; Ying Peng; Dianrong Xiu
Journal:  Gland Surg       Date:  2021-01

Review 3.  Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma.

Authors:  Vikrant Rai; Swati Agrawal
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

4.  B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.

Authors:  Claudia Minici; Elena Rigamonti; Marco Lanzillotta; Antonella Monno; Lucrezia Rovati; Takashi Maehara; Naoki Kaneko; Vikram Deshpande; Maria Pia Protti; Lucia De Monte; Cristina Scielzo; Stefano Crippa; Paolo Giorgio Arcidiacono; Erica Dugnani; Lorenzo Piemonti; Massimo Falconi; Shiv Pillai; Angelo A Manfredi; Emanuel Della-Torre
Journal:  Oncoimmunology       Date:  2020-07-16       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.